Key 2026 clinical milestones: The recurrent cSCC pivotal trial is nearing completion with last patient treatments expected imminently and topline data planned for H2 2026, while a GBM pilot safety ...
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing ...
Our CVIS (Cardiovascular Information Management System) is a unique software solution that empowers you to improve the clinical and financial performance of your cardiology department. Clinical ...
Taysha Gene Therapies (TSHA) reported a net loss of $109.0 million for the full year ending December 31, 2025, translating to a loss of $0.34 per share. This marks an increase from the $89.3 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results